RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its price objective reduced by Cantor Fitzgerald from $44.00 to $40.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Cantor Fitzgerald’s price target indicates a potential upside of 107.36% from the stock’s current price.
Several other equities research analysts also recently weighed in on RAPT. Piper Sandler reduced their price target on RAPT Therapeutics from $34.00 to $33.00 in a report on Thursday, December 8th. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, January 4th. The Goldman Sachs Group started coverage on RAPT Therapeutics in a report on Thursday, December 1st. They set a “buy” rating and a $27.00 price objective on the stock. HC Wainwright reduced their price objective on RAPT Therapeutics from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Guggenheim started coverage on RAPT Therapeutics in a report on Wednesday, January 4th. They set a “buy” rating and a $55.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, RAPT Therapeutics currently has an average rating of “Buy” and an average target price of $41.38.
RAPT Therapeutics Stock Performance
Shares of NASDAQ RAPT opened at $19.29 on Wednesday. The business’s 50 day moving average price is $27.19 and its 200-day moving average price is $23.36. RAPT Therapeutics has a fifty-two week low of $9.85 and a fifty-two week high of $32.45. The company has a market cap of $576.96 million, a price-to-earnings ratio of -7.56 and a beta of 0.46.
Insider Buying and Selling at RAPT Therapeutics
Institutional Trading of RAPT Therapeutics
A number of institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. boosted its position in shares of RAPT Therapeutics by 10.0% in the 4th quarter. Alliancebernstein L.P. now owns 30,900 shares of the company’s stock worth $612,000 after purchasing an additional 2,800 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new stake in RAPT Therapeutics during the 4th quarter worth about $1,453,000. State of Wisconsin Investment Board lifted its position in RAPT Therapeutics by 18.8% during the 4th quarter. State of Wisconsin Investment Board now owns 28,774 shares of the company’s stock worth $570,000 after acquiring an additional 4,552 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in RAPT Therapeutics by 165.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 281,875 shares of the company’s stock worth $5,581,000 after acquiring an additional 175,585 shares during the period. Finally, Legal & General Group Plc lifted its position in RAPT Therapeutics by 14.1% during the 4th quarter. Legal & General Group Plc now owns 10,278 shares of the company’s stock worth $204,000 after acquiring an additional 1,268 shares during the period.
About RAPT Therapeutics
Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.